Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Dudley Website

Mark E. Dudley, Ph.D.

Selected Publications
1)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013. [Journal]
2)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. [Epub ahead of print], 2013. [Journal]
3)  Dudley ME.
A major player "gets in the act".
J. Immunother. 35: 595-7, 2012. [Journal]
4)  Restifo NP, Dudley ME, Rosenberg SA.
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nat. Rev. Immunol. 12: 269-81, 2012. [Journal]
5)  Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ.
Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma.
Otolaryngol Head Neck Surg. 147: 744-9, 2012. [Journal]
6)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012. [Journal]
7)  Somerville RP, Dudley ME.
Bioreactors get personal.
Oncoimmunology. 1: 1435-1437, 2012. [Journal]
8)  Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME.
Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor.
J Transl Med. 10: 69, 2012. [Journal]
9)  Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA.
Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application.
J. Immunother. 35: 430-9, 2012. [Journal]
10)  Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM.
IRF5 gene polymorphisms in melanoma.
J Transl Med. 10: 170, 2012. [Journal]
11)  Yao X, Ahmadzadeh M, Lu Y, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF.
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
Blood. 119: 5688-96, 2012. [Journal]
12)  Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US.
Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
World J Surg Oncol. 10: 113, 2012. [Journal]
13)  Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA.
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.
Clin. Cancer Res. 18: 5212-23, 2012. [Journal]
14)  Stroncek DF, Berger C, Cheever MA, Childs RW, Dudley ME, Flynn P, Gattinoni L, Heath JR, Kalos M, Marincola FM, Miller JS, Mostoslavsky G, Powell DJ, Rao M, Restifo NP, Rosenberg SA, O'Shea J, Melief CJ.
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
J Transl Med. 10: 48, 2012. [Journal]
15)  Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G.
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?.
Mol. Ther. 20: 246-9, 2012. [Journal]
16)  Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA.
Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.
J. Immunother. 35: 283-92, 2012. [Journal]
17)  Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US.
The stoichiometric production of IL-2 and IFN-? mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Sci Transl Med. 4: 149ra120, 2012. [Journal]
18)  Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, van Rooij N, Linnemann C, van Buuren MM, Urbanus JH, Beltman JB, Thor Straten P, Li YF, Robbins PF, Besser MJ, Schachter J, Kenter GG, Dudley ME, Rosenberg SA, Haanen JB, Hadrup SR, Schumacher TN.
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
Oncoimmunology. 1: 409-418, 2012. [Journal]
19)  Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME.
Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes.
J. Immunother. 35: 400-8, 2012. [Journal]
20)  Dudley ME.
Adoptive cell therapy for patients with melanoma.
J Cancer. 2: 360-2, 2011. [Journal]
21)  Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA.
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Clin. Cancer Res. 17: 6287-97, 2011. [Journal]
22)  Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME.
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
J. Immunother. 34: 651-61, 2011. [Journal]
23)  Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy.
Clin Cancer Res. 17: 4550-7, 2011. [Journal]
24)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol. Ther. 19: 620-6, 2011. [Journal]
25)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011. [Journal]
26)  Yang S, Dudley ME, Rosenberg SA, Morgan RA.
A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
J. Immunother. 33: 648-58, 2010. [Journal]
27)  Morgan RA, Dudley ME, Rosenberg SA.
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Cancer J. 16: 336-41, 2010. [Journal]
28)  Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA.
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
Mol. Ther. 18: 843-51, 2010. [Journal]
29)  Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
CD8+ enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Clin. Cancer Res. 16: 6122-31, 2010. [Journal]
30)  Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME.
Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
J. Immunother. 33: 547-56, 2010. [Journal]
31)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DN, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19.
Blood. 116: 4099-102, 2010. [Journal]
32)  Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I.
Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy.
Ann. Surg. Oncol. 17: 163-70, 2010. [Journal]
33)  Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM.
Successful treatment of melanoma brain metastases with adoptive cell therapy.
Clin. Cancer Res. 16: 4892-8, 2010. [Journal]
34)  Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS.
Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.
J. Thorac. Cardiovasc. Surg. 140: 1276-82, 2010. [Journal]
35)  Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC.
Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.
J. Immunother. 33: 840-7, 2010. [Journal]
36)  Rosenberg SA, Dudley ME.
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
Curr. Opin. Immunol. 21: 233-40, 2009. [Journal]
37)  Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood. 114: 535-46, 2009. [Journal]
38)  Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME.
Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.
J. Immunother. 32: 870-4, 2009. [Journal]
39)  Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB.
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology. 116: 981-989.e1, 2009. [Journal]
40)  Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME.
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
J. Immunol. Methods. 345: 90-9, 2009. [Journal]
41)  Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
Blood. 114: 1537-44, 2009. [Journal]
42)  Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, Morgan RA, Rosenberg SA.
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Hum. Gene Ther. 19: 496-510, 2008. [Journal]
43)  Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA.
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
J. Clin. Oncol. 26: 5233-9, 2008. [Journal]
44)  Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nat. Rev. Cancer. 8: 299-308, 2008. [Journal]
45)  Rosenberg SA, Dudley ME, Restifo NP.
Cancer immunotherapy.
N. Engl. J. Med. 359: 1072, 2008. [Journal]
46)  Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME.
Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy.
J. Immunother. 31: 742-51, 2008. [Journal]
47)  Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ, Dudley ME, Morgan RA, Rosenberg SA.
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.
Hum. Gene Ther. 19: 1219-32, 2008. [Journal]
48)  Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB.
A T-cell receptor associated with naturally occurring human tumor immunity.
Proc. Natl. Acad. Sci. U.S.A. 104: 19073-8, 2007. [Journal]
49)  Dudley ME, Rosenberg SA.
Adoptive cell transfer therapy.
Semin. Oncol. 34: 524-31, 2007. [Journal]
50)  Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA.
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
J. Immunol. 177: 6527-39, 2006. [Journal]
51)  Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science. 314: 126-9, 2006. [Journal]
52)  Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA.
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
J. Immunol. 177: 6548-59, 2006. [Journal]
53)  Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
J. Clin. Oncol. 23: 2346-57, 2005. [Journal]
54)  Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF.
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
J. Immunother. 28: 258-67, 2005. [Journal]
55)  Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA.
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Hum. Gene Ther. 16: 457-72, 2005. [Journal]
56)  Powell DJ, Dudley ME, Robbins PF, Rosenberg SA.
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Blood. 105: 241-50, 2005. [Journal]
57)  Rosenberg SA, Dudley ME.
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Proc. Natl. Acad. Sci. U.S.A. 101 Suppl 2: 14639-45, 2004. [Journal]
58)  Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA.
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
J. Immunol. 173: 7125-30, 2004. [Journal]
59)  Zhou J, Dudley ME, Rosenberg SA, Robbins PF.
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
J. Immunother. 28: 53-62, 2004. [Journal]
60)  Nagorsen D, Servis C, Lévy N, Provenzano M, Dudley ME, Marincola FM, Lévy F.
Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.
Cancer Immunol. Immunother. 53: 817-24, 2004. [Journal]
61)  Zhou J, Dudley ME, Rosenberg SA, Robbins PF.
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
J. Immunol. 173: 7622-9, 2004. [Journal]
62)  Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF.
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
J. Immunol. 172: 6057-64, 2004. [Journal]
63)  Dudley ME, Rosenberg SA.
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Nat. Rev. Cancer. 3: 666-75, 2003. [Journal]
64)  Nagorsen D, Panelli M, Dudley ME, Finkelstein SE, Rosenberg SA, Marincola FM.
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Gene Ther. 10: 1754-65, 2003. [Journal]
65)  Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
J. Immunother. 26: 385-93, 2003. [Journal]
66)  Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA.
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
J. Immunother. 26: 332-42, 2003. [Journal]
67)  Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
J. Immunol. 171: 3287-95, 2003. [Journal]
68)  Dudley ME.
To bead or not to bead.
J. Immunother. 26: 187-9, 2003. [Journal]
69)  Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA.
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
J. Immunother. 25: 243-51, 2002. [Journal]
70)  Dudley ME.
A stimulating presentation.
Nat. Biotechnol. 20: 125-6, 2002. [Journal]
71)  Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science. 298: 850-4, 2002. [Journal]
72)  Monsurrò V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM.
Functional heterogeneity of vaccine-induced CD8(+) T cells.
J. Immunol. 168: 5933-42, 2002. [Journal]
73)  Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA.
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
J. Immunother. 24: 363-73, 2001. [Journal]
74)  Monsurrò V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, Marincola FM.
Kinetics of TCR use in response to repeated epitope-specific immunization.
J. Immunol. 166: 5817-25, 2001. [Journal]
75)  Karas M, Zaks TZ, Yakar S, Dudley ME, LeRoith D.
TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis.
Hum. Immunol. 62: 32-8, 2001. [Journal]
76)  Surman DR, Dudley ME, Overwijk WW, Restifo NP.
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
J. Immunol. 164: 562-5, 2000. [Journal]
77)  Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P.
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
Hum. Gene Ther. 11: 2377-87, 2000. [Journal]
78)  Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA.
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Cancer J. 6: 69-77, 2000. [Journal]
79)  Dudley ME, Nishimura MI, Holt AK, Rosenberg SA.
Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response.
J. Immunother. 22: 288-98, 1999. [Journal]
80)  Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC.
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
J. Immunol. 162: 989-94, 1999. [Journal]
81)  Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE.
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
Nat. Med. 4: 321-7, 1998. [Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 5/13/2013.